Objetivo Blood cells are produced in the bone marrow, which contains two distinct adult stem cell types: haematopoietic stem cells (HSCs), that generate all blood and immune cells, and mesenchymal stem cells (MSCs), thought to form the skeleton. HSCs traffic between bone marrow and circulation, what allows for life-saving clinical transplantation. Our previous work has shown that HSC numbers in blood are regulated by the central pacemaker in the brain, which reaches bone marrow nestin+ MSCs through the nerves. Contrarily to what it was believed, our recent data suggest that HSC-niche MSCs are different from those that form the skeleton and share instead a common origin with peripheral nerves and supporting glial cells. Thus, tight regulation of the bone marrow stem-cell niche in vertebrates might build upon developmental relationships of its cellular components. Moreover, we have shown that damage to this regulatory network is essential for the manifestation of myeloproliferative neoplasms, diseases that were previously thought to be driven solely by mutated HSCs. Also, JAK inhibitors (blocking the most frequent HSC mutation found in myeloproliferative neoplasms) cannot eradicate leukaemia stem cells. Our recent data has uncovered a selective regulation of normal and leukaemic haematopoietic progenitor maintenance, survival and division by sex hormones (oestrogens). These results might explain gender differences in blood cancer incidence and they also offer a new way of targeting leukaemia stem cells with clinically approved drugs. Nevertheless, we anticipate that the ideal future treatment of myeloproliferative diseases should target both leukaemia stem cells and their microenvironment. We have shown that protection or rescue of the niche is able to control the expansion of mutated cells. We aim to study this novel neuroendocrine regulation of bone marrow stem cells that will potentially fructify in new therapies for incurable myeloproliferative diseases. Ámbito científico medical and health sciencesbasic medicineimmunologymedical and health sciencesmedical biotechnologycells technologiesstem cellsnatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesclinical medicinetransplantationmedical and health sciencesclinical medicineoncologyleukemia Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-CoG-2014 - ERC Consolidator Grant Convocatoria de propuestas ERC-2014-CoG Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-COG - Consolidator Grant Institución de acogida THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE Aportación neta de la UEn € 1 594 500,00 Dirección TRINITY LANE THE OLD SCHOOLS CB2 1TN Cambridge Reino Unido Ver en el mapa Región East of England East Anglia Cambridgeshire CC Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 594 500,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE Reino Unido Aportación neta de la UEn € 1 594 500,00 Dirección TRINITY LANE THE OLD SCHOOLS CB2 1TN Cambridge Ver en el mapa Región East of England East Anglia Cambridgeshire CC Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 594 500,00
